Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	125.05	134.55	7.42	13.17	54.59	18.92
Cash & Short-Term Investments	125.05	134.55	7.42	13.17	54.59	18.92
Cash Growth	13.50%	1714.51%	-43.71%	-75.87%	188.52%	424.15%
Accounts Receivable	-	-	-	-	1.06	2.18
Other Receivables	-	0.61	0.14	1.92	3.74	2.21
Receivables	-	0.61	0.14	1.92	4.8	4.39
Inventory	-	-	-	0.02	0.04	0
Prepaid Expenses	1.83	3.71	0.84	1.29	2.37	2.66
Restricted Cash	0.06	0.02	0	0.02	0.05	0.04
Total Current Assets	126.94	138.89	8.4	16.42	61.85	26.01
Property, Plant & Equipment	0.95	1.21	1.97	2.41	2.7	1.61
Goodwill	10.5	10.5	10.5	14.41	14.41	14.41
Other Intangible Assets	-	-	-	-	0.04	1.59
Other Long-Term Assets	0.13	0.13	0.13	0.13	1.23	0.15
Total Assets	138.52	150.73	20.99	33.37	80.21	43.76
Accounts Payable	0.68	0.28	0.45	2.88	3.37	2.57
Accrued Expenses	4.57	5.22	1.76	10.51	14.29	8.86
Current Portion of Long-Term Debt	-	-	-	5.93	-	-
Current Portion of Leases	-	0.57	0.54	0.53	0.49	0.43
Current Unearned Revenue	-	-	-	0.09	-	-
Other Current Liabilities	0.36	0.89	1.87	2.17	1.74	3.36
Total Current Liabilities	5.62	6.96	4.62	22.11	19.89	15.23
Long-Term Debt	-	-	-	13.49	32.83	-
Long-Term Leases	-	0.35	1.37	1.71	2.02	1.04
Long-Term Deferred Tax Liabilities	0.28	0.27	0.16	0.14	0.11	0.09
Other Long-Term Liabilities	10.02	10.12	7.55	6.83	2.28	2.84
Total Liabilities	15.91	17.7	13.69	44.28	57.13	19.19
Common Stock	0.01	0.01	0	-	0.01	0.08
Additional Paid-In Capital	506.02	503.29	342.44	292.91	285.24	202.28
Retained Earnings	-383.41	-370.26	-335.13	-303.82	-262.17	-177.79
Total Common Equity	122.62	133.03	7.3	-10.92	23.08	24.56
Shareholders' Equity	122.62	133.03	7.3	-10.92	23.08	24.56
Total Liabilities & Equity	138.52	150.73	20.99	33.37	80.21	43.76
Total Debt	-	0.92	1.9	21.66	35.34	1.46
Net Cash (Debt)	125.05	133.63	5.51	-8.49	19.25	17.46
Net Cash Growth	15.41%	2324.31%	-	-	10.28%	645.41%
Net Cash Per Share	12.62	17.83	19.85	-216.49	531.87	684.21
Filing Date Shares Outstanding	10.83	10.67	1.03	0.06	0.04	0.56
Total Common Shares Outstanding	10.83	10.47	0.8	0.04	0.04	0.55
Working Capital	121.33	131.93	3.78	-5.7	41.96	10.78
Book Value Per Share	11.32	12.70	9.11	-277.78	589.35	44.33
Tangible Book Value	112.11	122.53	-3.2	-25.32	8.64	8.57
Tangible Book Value Per Share	10.35	11.70	-3.99	-644.47	220.48	15.46
Machinery	-	0.28	0.28	0.34	0.24	0.21
Leasehold Improvements	-	0.9	0.9	0.74	0.74	0.66

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q